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Abstract
Background: Heart rate (HR) reduction is associated with improved outcomes in patients 
with heart failure (HF) and biomarkers can be a valuable diagnostic tool in HF management. 
The primary aim of our study was to evaluate the short-term (6 months) effect of ivabradine on 
N-terminal pro B-type natriuretic peptide (NT-proBNP), CA-125, and cystatin-C values in sys-
tolic HF outpatients, and secondary aim was to determine the relationship between baseline HR 
and the NT-proBNP, CA-125, cystatin-C, and clinical status variation with ivabradine therapy.
Methods: Ninety-eight patients (mean age: 65.81 ± 10.20 years; 33 men), left ventricular  
ejection fraction < 35% with Simpson method, New York Heart Association (NYHA) class II–III,  
sinus rhythm and resting HR > 70/min, optimally treated before the study were included. 
Among them, two matched groups were formed: the ivabradine group and the control group. 
Patients received ivabradine with an average (range of 10–15) mg/day during 6 months of 
follow-up. Blood samples for NT-proBNP, CA-125, and cystatin-C were taken at baseline and 
at the end of a 6-month follow-up in both groups.
Results: There was a significant decrease in NYHA class in the ivabradine group (2.67 ± 
± 0.47 vs. 1.85 ± 0.61, p < 0.001). When ivabradine and control groups were compared,  
a significant difference was also found in NHYA class 6 months later (p = 0.013). A significant  
decrease was found in HR in the ivabradine and control groups (84.10 ± 8.76 vs. 68.36 ±  
± 8.32 bpm, p = 0.001; 84.51 ± 10 vs. 80.40 ± 8.3 bpm, p = 0.001). When both groups were 
compared, a significant difference was also found in HR after 6 months (p = 0.001). A signifi-
cant decrease was found in cystatin-C (2.10 ± 0.73 vs. 1.50 ± 0.44 mg/L, p < 0.001), CA-125  
(30.09 ± 21.08 vs. 13.22 ± 8.51 U/mL, p < 0.001), and NT-proBNP (1,353.02 ± 1,453.77 
vs. 717.81 ± 834.76 pg/mL, p < 0.001) in the ivabradine group. When ivabradine and control 
groups were compared after 6 months, a significant decrease was found in all HF parameters 
(respectively; cystatin-C: p = 0.001, CA-125: p = 0.001, NT-proBNP: p = 0.001). Creatinine 
level was significantly decreased and glomerular filtration rate (GFR) was significantly in-
creased in the ivabradine group (1.02 ± 0.26 vs. 0.86 ± 0.17, creatinine: p = 0.001; 79.26 ±  
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± 18.58 vs. 92.48 ± 19.88, GFR: p = 0.001). There was no significant correlation between 
NYHA classes (before and after ivabradine therapy) and biochemical markers, or HR.
Conclusions: In the outpatients with systolic HF, persistent resting HF > 70/min with opti-
mal medical therapy, the NT-proBNP, CA-125, and cystatin-C reductions were obtained with 
ivabradine treatment. Measurement of NT-proBNP, CA-125, and cystatin-C may prove to be 
useful in biomarker panels evaluating ivabradine therapy response in HF patients. (Cardiol J 
2015; 22, 5: 501–509)
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Introduction
Heart failure (HF) is a clinical syndrome char-
acterized by the inability of the heart to pump 
enough blood to supply the body’s demands [1]. 
Enhanced heart rate (HR), which is general-
ly observed in patients with congestive HF, at-
tenuates the decrease in cardiac output or pre-
serves cardiac output at the cost of impaired left 
ventricular (LV) filling, increased myocardial O2 
consumption, and reduced coronary perfusion 
time. The developments of LV dysfunction and/or 
congestive HF were observed after persistent 
tachycardia [2–5].
Epidemiological and clinical studies indicate 
that a higher resting HR in sinus rhythm is as-
sociated with increased morbidity and mortality 
in the general population and in patients with 
cardiovascular disease. HR reduction is associ-
ated with improved outcomes in patients with 
HF, because some of the beneficial effects of 
b-blockade may be attributed to HR reduction 
and the effects of b-blockers on cardiac function 
and survival are correlated with the magnitude of 
the HR reduction [6–8]. However, some patients 
cannot tolerate target dosages of b-blockers and, 
when resting HRs remain elevated despite efforts 
to optimize b-blocker dose, there is potential 
benefit from further HR reduction. Ivabradine is 
a selective inhibitor of the cardiac pacemaker If 
current, which modulates pacemaker activity in 
the sino-atrial node, providing pure HR reduction 
without modifying atrioventricular or intraven-
tricular conduction or contractility and has no effect 
on blood pressure. HR reduction with ivabradine 
improves LV filling by prolonging diastolic time 
and increases stroke volume [9–11]. It improves 
event-free survival, exercise capacity, and quality 
of life in patients with systolic HF and resting HR 
> 70/min [12, 13]. However, it remains unclear 
what the effect of ivabradine is on HF markers. 
Recently, new biomarkers might have an additional 
contribution to improving the prognostic assess-
ment in patients with HF. The objective of our 
study was, accordingly, to evaluate in stable outpa-
tients with systolic HF the short-term (6-month) 
effect of ivabradine on HF markers.
Methods
Patients
Ninety-eight ambulatory, clinically stable 
symptomatic outpatients with systolic chronic 
HF (≥ 4 weeks), who had been hospitalized for 
worsening HF in the 12 months before inclu-
sion, on optimized standard medical therapy were 
consecutively included and randomly allocated to 
the ivabradine group and non-ivabradine group 
between October 2013 and August 2014.
Inclusion criteria
Patients with chronic HF, on optimized medical 
therapy according to European Society of Cardiol-
ogy guidelines, with LV ejection fraction (LVEF) 
< 35% according to the Simpson method, New York 
Heart Association (NYHA) class II–III, and sinus 
rhythm and resting HR > 70/min were eligible for 
inclusion in the study.
Exclusion criteria
Patients who presented with the following, 
were excluded from the study: acute decompen-
sation (acute coronary syndromes and acute HF); 
hemodynamically significant valve disease; cer-
ebrovascular events during the previous 6 months; 
dysfunctional prosthetic heart valve; obstructive 
or non-obstructive cardiomyopathy; uncorrected 
congenital heart disease; active myocarditis; a his-
tory of resuscitation from sudden death; an absence 
of stable sinus rhythm, severe arrhythmias; HR 
< 60 bpm; sick sinus syndrome; second-degree and 
third-degree atrioventricular block; severe obesity 
(body mass index > 36 kg/m²); established or sus-
pected pulmonary diseases (vital capacity < 80% or 
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forced expiratory volume in 1 s < 80% of age spe-
cific and sex-specific reference values); hemoglobin 
≤ 11 g/dL; treatment with non-dihydropyridine 
calcium-channel blockers, class I antiarrhythmic 
agents, strong inhibitors of cytochrome P450-3A4, 
or QT interval–prolonging medications; acute and 
chronic kidney failure; pregnancy; hypo- and hy-
perthyroidism or acute infections.
Study protocol
This was a 6-month, open-label, blinded, 
parallel-group, interventional, prospective-cohort 
study. The baseline evaluation comprised physical 
examination; NYHA class; 12-lead electrocardi-
ography (ECG); blood sampling for laboratory 
measurements, including cystatin-C, CA-125, and 
N-terminal pro-B-type natriuretic peptide (NT-
-proBNP). Echocardiographic imaging was per-
formed using Vivid 7 equipment (GE Vingmed 
Ultrasound AS, Horten, Norway) with phased-array 
2.5-MHz multi-frequency transducers. Accordingly, 
all patients underwent screening echocardiography 
to determine their suitability for the trial by the 
evaluation of strict criteria for EF. Images were 
saved in digital format and stored on a secure 
server for offline analysis. LVEF was determined 
using a modified Simpson biplane method. All 
patients were receiving standard HF therapy 
for their comorbidities (diuretics, angiotensin-
converting enzyme inhibitors (ACEI), angiotensin 
II antagonists, aldosterone receptor blockers, and 
b-adrenoreceptor blockers), at their maximum 
doses tolerated in both groups. Investigators main-
tained participants as closely as possible to target 
dosages, notably with b-blockade. Patients in the 
ivabradine group were allocated to ivabradine at 
a starting dose of 5 mg twice daily; doses were 
adjusted upward or downward (2.5, 5, or 7.5 mg 
twice daily) at every visit according to HR at 
rest and tolerability. To check for the presence of 
bradycardia, patients were seen for the first time 
on the 7th day after the initiation of treatment. In 
case of a resting HR < 50 bpm or the occurrence of 
signs or symptoms related to bradycardia, the dose 
of ivabradine was to be reduced to 2.5 mg twice 
daily, or if these persisted after dose reduction, 
the study medication was to be withdrawn. At least 
monthly visits to the clinic were scheduled after 
the first visit on the 7th day after the initiation of 
treatment. At 6 months, a full clinical evaluation, 
including NYHA class assessment and laboratory 
workup including NT-proBNP, cystatin-C and CA- 
-125 determination, was performed in both groups. 
The variation in relation to the baseline value (for 
the HR) was determined as absolute (initial final) 
and relative (percent) variation. The study adhered 
to the Declaration of Helsinki and was approved 
by the institutional Ethics Committee. Informed 
consent was obtained from all subjects before 
involvement in the study.
NT-proBNP measurement
Peripheral venous blood samples were drawn 
between 8 and 9 am after a 30-min rest in the 
supine position. Plasma samples were frozen at 
–70°C until assay. NT-proBNP was determined 
with an Elecsys 20.10 bench-top analyzer (Roche 
Diagnostics, Meylan, France) with proBNP reagent 
pack (Roche Diagnostics). BNP was measured with 
BNP Triage reagent pack (Biosite Inc. San Diego, 
CA, USA).
Cystatin-C measurement
Cystatin-C serum levels were measured us-
ing a sandwich enzyme-linked immunoassay kit 
(Biovendor Research and Diagnostic Products) 
from peripheral venous blood samples.
CA-125 measurement
Serum levels of CA-125 were determined with 
use of the commercially available Tumor Markers 
CA 125 AxSYM® System (Abbott Laboratories; 
Abbott Park i2000, Ill) from peripheral venous blood 
samples like BNP and cystatin-C.
Statistical analysis
Continuous variables were expressed as mean 
± standard deviation (SD) and categorical variables 
as percentages. To compare the changes from 
baseline to 6 months, a paired Student’s t-test was 
used, and the c2 test was used in the comparison of 
percentage data. Independent samples T-test was 
used to compare data between two different groups. 
The relationship between parameters was deter-
mined with the Pearson correlation coefficient. 
A p value of < 0.05 was considered statistically 
significant. All tests were 2-tailed and performed 
using a commercially available package (SPSS for 
Windows, version 17.0, SPSS Inc).
Results
Clinical characteristics
Ninety-eight patients (65 female, 33 male) 
were studied. The patients in ivabradine group 
had a mean age of 65.24 ± 8.70 years, and were 
overweight. At baseline, there were no differences 
in LVEF, NHYA class, hypertension, diabetes mel-
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litus, ischemic heart disease history, between the 
ivabradine and non-ivabradine groups. Concomitant 
medication was as follows: diuretic (96–94%) and 
adrenergic b-blocker (90–94%) agents were the 
most commonly employed in both groups; 68% 
also received mineralocorticoid receptor antago-
nists (MRA medications) and 88% ACEIs/angioten-
sin receptors blockers in the ivabradine group. In 
total, 16 patients had cardiac pacemakers (CRT-D) 
(Table 1).
It is important to note that 14 patients de-
veloped congestive HF and 3 patients developed 
shortly paroxysmal atrial fibrillation once under 
optimal medical treatment in the non-ivabradine 
group during 6 months of follow-up. Sinus rhythm 
was achieved by intravenous metoprolol treat-
ment. Nine patients had remaining bundle branch 
block on ECG in the non-ivabradine group. In the 
ivabradine group, 9 patients developed congestive 
HF and 7 of 9 had cardiac pacemaker (CRT-D). Dur-
ing the 6-month follow-up there were no deaths. 
No patients were dropped out of the study in both 
groups. Eight patients had the furosemide dosage 
increased and 3 patients had furosemide dosage 
decreased in the non-ivabradine group. Also, 
5 patients stopped spironolactone due to potassium 
increase. In the ivabradine group, 4 patients had 
the furosemide dosage increased and 2 patients 
had furosemide dosage decreased. Of the patients 
on b-blockers (87%), 26 achieved the target dose 
in the ivabradine group and 29 achieved it in the 
non-ivabradine group.
Patients received ivabradine with an aver-
age 10.30 ± 3.29 mg/day during the 6 months 
of follow-up. There was a significant decrease 
in NYHA class between the groups at baseline 
(before ivabradine) and at 6 months later (after 
ivabradine) (2.67 ± 0.47 vs. 1.85 ± 0.61, p < 0.001). 
When ivabradine and non-ivabradine groups 
were compared, a significant difference was also 
found in NHYA class after 6 months (p = 0.013). 
A significant decrease was found in HR in the iv-
abradine and non-ivabradine groups (84.10 ± 8.76 
vs. 68.36 ± 8.32 bpm, p = 0.001; 84.51 ± 10 vs. 
80.40 ± 8.3 bpm, p = 0.001). When both groups 
were compared, a significant difference was also 
found in HR after 6 months (p = 0.001) (Table 2). 
A significant decrease was found in cystatin-C 
(2.10 ± 0.73 vs. 1.50 ± 0.44, p < 0.001), CA-125 
(30.09 ± 21.08 U/mL vs. 13.22 ± 8.51 U/mL, 
Table 1. Clinical and demographic characteristics of the study population.
Ivabradine group Non-ivabradine group P
Demographics
Number of patients 49 49 > 0.05
Age [yeras] 65.24 ± 8.70 66.38 ± 11.57 0.58
Male/female 16/33 (33/67%) 17/32 (35/65%) 0.83
Weight [kg] 78.59 ± 8.67 75.34 ± 10.16 0.09
NYHA class II/III 16/33 (33/67%) 21/28 (43/57%) 0.29
LVEF [%] 26.42 ± 5.28 27.75 ± 5.24 0.21
Heart rate 84.10 ± 8.76 84.51 ± 10 0.79
Concomitant diseases
Hypertension 30 (61%) 33 (67%) 0.52
Diabetes mellitus 17 (34%) 11 (22%) 0.18
Dyslipidemia 15 (31%) 13 (27%) 0.65
Ischemic heart disease 47 (96%) 43 (88%) 0.14
Treatment at inclusion
Furosemide 47 (96%) 46 (94%) 0.64
Spironolactone 35(71%) 32 (65%) 0.51
Beta-blocker 44 (90%) 46 (94%) 0.46
ACEI/ARB 45 (92%) 42 (86%) 0.33
Statin 44 (90%) 40 (82%) 0.24
CRT-D 7 (14%) 9 (18%) 0.58
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; CRT-D — cardiac resynchronization therapy-ICD 
(implantable cardioverter defibrillator); LVEF — left ventricular ejection fraction; NYHA — New York Heart Association
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p < 0.001), and NT-proBNP (1,353.02 ± 1,453.77 
vs. 717.81 ± 834.76 pg/mL, p < 0.001) in the 
ivabradine group. But there was no significant de-
crease in the non-ivabradine group in terms of cystatin-C 
(2.28 ± 0.69 vs. 2.25 ± 0.49 mg/L, p = 0.62), CA-125 
(36.69 ± 23.89 vs. 33.98 ± 19.94 U/mL, p = 0.058) 
and NT-proBNP (1,383.42 ± 1,064.62 vs. 1,323.26 ± 
± 979.26 pg/mL, p = 012). When ivabradine 
and non-ivabradine group were compared after 
6 months, a significant decrease was found in all HF 
parameters (respectively; cystatin-C: p = 0.001, 
CA-125: p = 0.001, NT-proBNP: p = 0.001) (Table 2).
White blood cell count was significantly lower in 
the control group at baseline and after 6 months com-
pared to the ivabradine group (baseline: p = 0.025, 
6 months: p = 0.001). Platelet count was sig-
nificantly lower in the ivabradine than in the non- 
-ivabradine group (ivabradine: p = 0.004, control: 
p = 0.007). Also, platelet count was significantly 
lower at baseline and at 6 months when ivabradine 
and non-ivabradine groups were compared (base-
line: p = 0.005, 6 months: p = 0.019). There was no 
statistical difference in hemoglobin level, glucose 
level, platelet distribution width and red cell distri-
bution width value between the groups at 6-month 
follow-up. But a significant increase was found 
in hematocrit level after the ivabradine therapy 
(p = 0.017). Mean platelet volume value was 
significantly lower in the non-ivabradine group 
(p = 0.001), but mean platelet volume value was 
significantly higher at baseline (p = 0.001) and at 
6 months (p = 0.001) in the non-ivabradine group 
compared to the ivabradine group. In addition, there 
was no significant change in fasting glucose level. 
Creatinine level was significantly decreased and 
glomerular filtration rate (GFR) was significantly 
increased in the ivabradine group (1.02 ± 0.26 vs. 
0.86 ± 0.17, creatinine: p = 0.001; 79.26 ± 18.58 
vs. 92.48 ± 19.88, GFR: p = 0.001). However, 
GFR was significantly decreased and no significant 
decrease was found in terms of creatinine in the 
non-ivabradine group (78.65 ± 20.45 vs. 71.12 ± 
± 16.54, GFR: p = 0.001; 0.94 ± 0.25 vs. 1.00 ± 
0.20, creatinine: p = 0.069) (Table 2).
There was no significant correlation between 
NYHA classes (before and after ivabradine therapy) 
or between biochemical markers, or HR (NYHA 
class before and after, cystatin-C before and after; 
before: p = 0.73, after: p = 0.98; NYHA class before 
and after, CA-125 before and after; before: p = 0.06, 
after: p = 0.76; NYHA class before and after, NT- 
-proBNP before and after; before: p = 0.16, after: 
p = 0.73; NYHA class before and after, HR before 
and after; before: p = 0.35, after: p = 0.07).
HR variation was 3.00 vs. 35.00 bpm. There 
was no significant correlation between HR variation 
and NT-proBNP, cystatin-C in the ivabradine group 
(p = 0.92, p = 0.56, respectively), yet a significant 
correlation between HR variation and CA-125 
was found in the ivabradine group (p = 0.02). 
Also, a significant correlation was found between 
HR variation and NT-proBNP in the non-ivabradine 
group (p = 0.003) (Table 3).
Discussion
This study demonstrates that in outpatients 
with systolic HF on optimized medical therapy and 
resting HR > 70/min, the expected HR reduction 
with ivabradine addition significantly decreases 
NT-proBNP, cystatin-C and CA-125 after 6 months.
HR reduction with b-blockers or with ivabra-
dine improves LV performance and has a positive 
effect on LV remodeling, reducing the risk of 
hospitalization and improving survival [10, 14, 15]. 
Busseuil et al. [16] demonstrated that selective 
HR reduction with ivabradine prevented the det-
rimental effects of hypercholesterolemia on LV 
myocardial performance. Ivabradine attenuated 
LV diastolic dysfunction, reduced left atrial and 
LV structural remodeling (interstitial fibrosis), 
and reduced LV collagen type I in hypercholester-
olemic rabbits. Ivabradine also improved left atrium 
fractional shortening. Circulating angiotensin II 
levels were significantly lowered by ivabradine 
and correlated with HR. Aldosterone levels also 
correlated with HR during treatment and were 
lower with ivabradine [16]. Results in experimental 
studies are consistent with the effects of ivabra-
dine on cardiac remodeling [11]. In a rat model 
of chronic mild HF, ivabradine preserved cardiac 
output and improved LV function and geometry 
[17]. These changes were linked to modifications 
in the extracellular matrix and in cardiac myocyte 
function. Ivabradine also had beneficial effects on 
the global cardiac remodeling process involved in 
HF, including optimization of energy consumption, 
reverse electrophysiological and structural cardiac 
remodeling [18]. Similar effects with ivabradine 
have been found by other workers in a rat model of 
chronic severe HF, including reductions in fibrosis, 
local renin–angiotensin–aldosterone system stimu-
lation, and sympathetic drive, as well as improve-
ment in endothelial function [19, 20].
The results of the SHIFT trial showed that 
treatment with ivabradine added to conventional 
therapy for HF was associated with an 18% reduc-
tion in the relative risk for the primary composite 
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endpoint of cardiovascular death or hospitalization 
for worsening HF [10]. It also had a positive effect 
on LV remodeling in the echocardiographic sub-
study of the BEAUTIFUL (morBidity-mortality 
EvAlUa-Tion of the If inhibitor ivabradine in pa-
tients with coronary disease and left ventricULar 
dysfunction) study [21].
NT-proBNP is a marker for the presence of 
LV systolic dysfunction and a prognostic marker 
for morbidity and mortality in HF. It is the inactive 
split product of the BNP [22]. NT-proBNP levels 
often decline after initiation and up-titration of HF 
therapy such as vasodilators and aldosterone block-
ers [23–25]. Persistently elevated (or rising) levels 
of NT-proBNP are predictive of poor outcome [26]. 
Several factors may influence the effect of drugs on 
the NT-proBNP values: the baseline value, severity 
of HF, and age [23]. Sargento et al. [27] found that 
the NT-proBNP reduction obtained by short-term 
ivabradine treatment correlates closely with the 
degree of HR reduction in systolic HF patients.
Cystatin-C, a cysteine protease inhibitor pro-
duced at a constant rate by nearly all human cells, 
is freely filtered by the renal glomerulus and 
excreted into the bloodstream. This protein has 
a low molecular weight and does not form a complex 
with other secreted proteins in the blood [28]. 
Cystatin-C independently predicts adverse events 
in chronic HF and is also an independent risk factor 
in the prognosis of patients with HF [29]. Shlipak et 
al. [30] showed the prognostic value of cystatin-C 
instable HF patients who had lower EF < 35%. Du-
pont et al. [31] found that cystatin-C was a strong 
predictor of adverse events in stable chronic HF, 
independent of traditional risk factors and BNP. 
Beside this, we found a significant increase in 
GFR and a significant decrease in creatinine level 
in the ivabradine group. This finding indicates that 
ivabradine treatment may improve renal perfusion 
in systolic HF in addition to cystatin-C reduction.
The CA-125 antigen as an ovarian cancer 
marker exhibits low specificity. Its elevated con-
centrations occur in different types of cancer and 
in non-gynecological diseases [32]. Elevated con-
centrations of this antigen also occur in HF and 
are connected with the patients’ poor prognosis 
[33]. Fluid overload and the inflammatory process 
are interactional and they mutually magnify their 
activities and secretion during the exacerbation 
of chronic HF. It has become increasingly clear 
that mechanical stress and inflammatory stimuli 
together initiate CA-125 synthesis [34]. In the 
course of HF, CA-125 is positively correlated with 
the NYHA functional class, the presence of pleural 
effusion, and pulmonary capillary wedge pres-
sure [35, 36]. Nunez et al. [37] found significant 
differences in CA-125 levels in patients with and 
without HF; patients with acute HF exhibited 
a 7-fold increase in mean CA-125 serum levels in 
comparison with control subjects. Also, Folga et 
al. [38] found that elevated values of NT-proBNP 
and CA-125 were independent death risk factors 
in advanced HF patients.
NT-proBNP, CA-125 and cystatin-C values 
were found to be higher in HF patients in different 
studies [27, 31, 35]. In this study, we have tried to 
assess the utility of old and new HF biomarkers 
with ivabradine therapy in HF patients. HF bio-
markers were decreased after ivabradine therapy 
in 6-month follow-ups. In addition, NYHA class 
and HR were decreased after ivabradine therapy 
in Sargento et al. [27] study at 3-month follow-up. 
However, we did not find a significant relationship 
between NYHA class decrease and biomarker (NT-
-proBNP, CA-125 and cystatin-C) decreases after 
ivabradine therapy. Also, we found no correlation 
Table 3. Relationship between heart rate and biochemical markers.
Ivabradine treatment Non-ivabradine group
Heart rate  
(before  
ivabradine)
Heart rate  
(after  
ivabradine)
Heart rate  
variation
Heart rate  
— baseline
Heart rate  
— 6 months 
later
Heart rate  
variation
r p r p r p r p r p r p
NT-proBNP* 0.02 0.89 0.06 0.66 0.01 0.92 –0.22 0.11 0.08 0.58 0.42 0.003#
Cystatin-C** 0.10 0.49 0.36 0.01# 0.08 0.56 –0.08 0.56 0.04 0.76 –0.6 0.68
CA-125*** 0.20 0.16 0.04 0.75 0.32 0.02# –0.08 0.54 0.07 0.60 0.13 0.35
#Statistically significat; *Comparison of heart rate (before and after ivabradine) and NT-proBNP (before and after ivabradine); **Comparison of 
heart rate (before and after ivabradine) and cystatin-C (before and after ivabradine); ***Comparison of heart rate (before and after ivabradine) 
and CA-125 (before and after ivabradine); NT-proBNP — N-terminal pro B-type natriuretic peptide
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between HR variation and NT-proBNP, cystatin-C. 
Conversely, a significant correlation between HR 
variation and CA-125 was found.
To the best of our knowledge, the present 
study is the first to disclose ivabradine effect on 
HF markers including NT-proBNP, CA-125, and 
cystatin-C. We found that the levels of all of these 
HF markers were decreased after ivabradine 
therapy at 6-month follow-up. This indicates that 
we may evaluate ivabradine therapy response in 
HF patients by following changes in blood levels 
of HF markers.
Limitations of the study
This was a single-center trial, which limits 
generalization but allows stronger trial control 
and adherence to study protocol. The intervention 
period was short. It is probable that a longer follow-
up would show more changes in variables such as 
NT-proBNP, CA-125, and cystatin-C and that a cor-
relation would be found between HR variation and 
biomarkers. Therefore, more studies are required 
to evaluate the effects observed in a larger number 
of patients for a longer period.
Conclusions
According to our study, in outpatients with 
systolic HF, persistent resting HF > 70/min with 
optimal medical therapy, NT-proBNP, CA-125, and 
cystatin-C reduction was obtained with ivabradine 
treatment. Only CA-125 correlated with HR vari-
ation. Measurement of NT-proBNP, CA-125, and 
cystatin-C may prove to be useful in biomarker 
panels evaluating ivabradine therapy response in 
HF patients.
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